Session Information
-
WCLC 2020
2020 World Conference on Lung Cancer
Conference Program for the 2020 World Conference on Lung Cancer in Singapore
Presentation Date(s):- January 28 - 31, 2021
- Total Presentations: 1597
All times listed are in Singapore time (GMT+8)
PL - Plenary
PS - Presidential Symposium
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
IS - Industry Symposium
JICC - Joint IASLC-CAALC-CSCO Session
January 28 Thu
Jan 28 Friday
January 29 Fri
Jan 29 Saturday
January 30 Sat
Jan 30 Sunday
January 31 Sun
Jan 31
-
+
JICC01 - Joint IASLC-CAALC-CSCO Session: The Truth and Myth of Oral Anti-VEGFR Inhibitors for Advance NSCLC
- 07:00 - 09:00
- 1/28/2021
- Location: Scientific Program Auditorium
- Not for CME Credit
- Type: Workshop
- Track: N.A.
-
+
JICC01.02 - Chair
07:00 - 07:00 | Presenter: Tony S. Mok
- Abstract
No abstract available for this presentation
-
+
IS03 - Industry Symposium Sponsored by Daiichi-Sankyo: Antibody Drug Conjugates (ADC) as Therapeutic Options for Advanced NSCLC: Opportunities and Challenges
- 11:45 - 12:45
- 1/28/2021
- Location: Industry Symposia Auditorium (via Industry Hub)
- Not for CME Credit
- Type: Industry Symposium
- Track:
-
+
IS03.01 - Welcome and Introduction
11:45 - 11:50 | Presenter: Tony S. Mok
- Abstract
No abstract available for this presentation
-
+
IS03.02 - Evolving Challenges for the Treatment of Advanced NSCLC
11:50 - 12:00 | Presenter: Tony S. Mok
- Abstract
No abstract available for this presentation
-
+
FP14 - Targeted Therapy - Clinically Focused
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Type: Posters (Featured)
- Track: Targeted Therapy - Clinically Focused
-
+
FP14.12 - Quality of Life and Subgroup Analysis in a Phase 3 Randomized Study of Ensartinib vs Crizotinib in ALK–Positive NSCLC Patients: eXalt3.
00:00 - 00:00 | Presenter: Yi-long Wu
- Abstract
Loading...
-
+
P03 - Early Stage/Localized Disease - Clinical Trials in Progress
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Early Stage/Localized Disease
-
+
P03.05 - CANOPY-N: Neoadjuvant Canakinumab and Pembrolizumab in Patients With Surgically Resectable Non-Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Jay M. Lee
- Abstract
Loading...
-
+
P19 - Locoregional and Oligometastatic Disease - Oligometastatic Disease
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Locoregional and Oligometastatic Disease
-
+
P19.01 - Local Ablative Radiotherapy on Oligo-Progression while Continued on EGFR-TKI in Advanced NSCLC Patients: A Longer Cohort
00:00 - 00:00 | Presenter: Florence Siu Ting Mok
- Abstract
Loading...
-
+
P35 - Pathology - Genomics
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Pathology, Molecular Pathology and Diagnostic Biomarkers
-
+
P35.15 - Molecular Epidemiology of KRAS G12C Mutations in Chinese Lung Cancer Patients
00:00 - 00:00 | Presenter: Herbert H Loong
- Abstract
Loading...
-
+
P76 - Targeted Therapy - Clinically Focused - EGFR
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Targeted Therapy - Clinically Focused
-
+
P76.67 - Safety and Efficacy of First-Line Dacomitinib in Advanced Non-Small Cell Lung Cancer by EGFR Mutation SUBtype in ARCHER 1050
00:00 - 00:00 | Presenter: Adam Pluzanski
- Abstract
Loading... -
+
P76.78 - Evaluation of the Development of Brain Metastases in Patients Treated with Dacomitinib or Gefitinib from ARCHER 1050 Study
00:00 - 00:00 | Presenter: Qing Zhou
- Abstract
Loading...
-
+
IS15 - Industry Symposium Sponsored by Amoy: Lung Cancer Biomarker Panel Testing
- 13:00 - 14:00
- 1/31/2021
- Location: Industry Symposia Auditorium (via Industry Hub)
- Not for CME Credit
- Type: Industry Symposium
- Track:
-
+
IS15.01 - Opening Remarks
13:00 - 13:03 | Presenter: Tony S. Mok
- Abstract
No abstract available for this presentation
-
+
IS15.02 - Biomarker for Lung Cancer: Right Patient, Right Time, Right Test
13:03 - 13:21 | Presenter: Tony S. Mok
- Abstract
No abstract available for this presentation
-
+
IS15.05 - Closing Remarks
13:57 - 14:00 | Presenter: Tony S. Mok
- Abstract
No abstract available for this presentation
-
+
MA11 - Expanding Targetable Genetic Alterations in NSCLC
- 14:15 - 15:15
- 1/31/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Mini Oral
- Track: Targeted Therapy - Clinically Focused
-
+
MA11.08 - Patient-Reported Outcomes from the Randomized Phase 3 CROWN Study of First-Line Lorlatinib versus Crizotinib in ALK+ NSCLC
14:40 - 14:45 | Presenter: Julien Mazieres
- Abstract
Loading...